health
Tambotatug Pelitecan Significantly Improves Survival Over Topotecan in Patients With Relapsed Small Cell Lung Cancer
By Info60 US Desk•Summary of reporting by Health Management Professionals Global Learning Ne•3d ago•0 views•
Results from the phase 3 TAISHAN-302 study demonstrated that tambotatug pelitecan significantly improved overall and progression-free survival compared with topotecan in patients with relapsed small cell lung cancer, supporting the B7-H3–directed antibody-drug conjugate as a potential new second-line standard of care.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Moody? Aggressive? You could have ‘irritable male syndrome’
New York Post
Ozempic and Wegovy linked to brain health risks from caloric cuts
Fox News
After 20 Miscarriages, Mom Celebrates Son’s First Birthday: ‘I Couldn’t Give Up’ (Exclusive)
Yahoo
5 Georgia siblings diagnosed with measles
WSB-TV
People Who Drink Their Own Pee Are Obsessed With AI, Using It to Reassure Themselves That It's a Miraculous Cure-All
Futurism